<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cunningham, Muriel</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Morrow, David A.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Ranolazine Reduces Recurrent Ischemia in Patients with Non-ST Elevation ACS</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2007</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2007-05-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">20-21</style></pages><abstract><style  face="normal" font="default" size="100%">Ranolazine is an anti-ischemic agent indicated for the treatment of chronic angina. Its effects occur without clinically significant changes in heart rate or blood pressure. However, because ranolazine is associated with a mild prolongation of the QTc interval (mean change approximately 6 ms), it currently is indicated only for patients who have not responded to other therapies. Because of this potentially worrisome prolongation of the QT interval, additional safety data were sought.</style></abstract><number><style face="normal" font="default" size="100%">1</style></number><volume><style face="normal" font="default" size="100%">7</style></volume></record></records></xml>